In a nutshell This phase 3 trial aims to evaluate how well aspirin can work to prevent recurrence of breast cancer. The main outcome to be investigated is invasive disease free survival. Other outcomes include overall survival (time from treatment until death from any cause) and the incidence of heart disease. This trial is taking place in 985...
Read MoreType(s) of breast cancer-Breast carcinoma Posts on Medivizor
Searching for patients with HER2 positive metastatic breast cancer to test palbociclib in combination with standard therapy.
In a nutshell This phase 3 trial aims to evaluate the effectiveness of palbociclib (Ibrance) in combination with standard treatments for HER2 positive breast cancer. The main outcome to be investigated is progression free survival. This trial is taking place in Alabama, Illinois, Iowa, Nebraska and Oklahoma in the United States. The details...
Read MoreRadiotherapy: before or after surgery for breast cancer stages I-III?
In a nutshell This study examined whether radiotherapy treatment before surgery could improve disease-free survival, especially for patients with estrogen-receptor positive (ER+) breast cancer (dependent on the hormone estrogen for growth). This study concluded that radiotherapy before surgery improved disease-free survival. Some background For...
Read MoreLooking at sexual health of breast cancer survivors
In a nutshell This study aimed to compare the sexual health of breast cancer survivors to that of women from the general population. This study concluded that breast cancer survivors had poorer sexual health when compared to women from the general population. Some background Post-treatment care is becoming more important in cancer patients...
Read MoreASCO 2017: Breast Cancer Research News
Video information: Breast cancer experts gathered at the 2017 American Society of Clinical Oncology meeting to discuss developments in research and treatment. Patient Power founder, Andrew Schorr, was on-site in Chicago and interviewed Dr. Julie Gralow, Director of Breast Medical Oncology at the Seattle Cancer Care Alliance. Dr. Gralow shares...
Read MoreComparing neoadjuvant options for HER2+ breast cancer
In a nutshell This study aimed to compare the pathological complete response (pCR) rates of two neoadjuvant therapy combinations for HER2 positive (HER2+, dependent on HER2 for growth) breast cancer. This study concluded that the combination of pertuzumab (Perjeta), trastuzumab (Herceptin) and chemotherapy resulted in higher pCR rates than...
Read MoreZoledronic acid as an option for HER2-negative breast cancer
In a nutshell This study aimed to investigate zoledronic acid in combination with chemotherapy as a treatment for HER2-negative breast cancer. This study concluded that the addition of zoledronic acid to chemotherapy has potential benefits for certain breast cancer patients. Some background HER2-negative breast cancer (BC) differs from...
Read MoreCan neoadjuvant therapy influence other treatments for breast cancer?
In a nutshell This study aimed to investigate whether neoadjuvant systemic therapy (NST) influenced the eligibility of HER2 positive breast cancer patients to undergo breast conserving therapy (BCT). This study concluded the use of NST can result in patients who are non-eligible for BCT converting to patients that are eligible for BCT. Some...
Read MoreComparing axillary lymph node ultrasound and fine needle aspiration in breast cancer
In a nutshell This study investigated whether patients with a suspicious axillary lymph node (ALN) but negative fine-needle aspiration result (FNA) can be considered as having node-negative disease (AUN). The study concluded that patients with suspicious ALN on ultrasound but negative FNA results can be treated as having node-negative disease. Some...
Read MoreThe accuracy and relevancy of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer
In a nutshell This study investigated the accuracy and reliability of sentinel lymph node biopsy (SNLB) before neoadjuvant systemic therapy (NAST) has begun in breast cancer patients. The study concluded that SLNB before NAST is highly reliable. The authors suggested that patients with a negative SLNB may be able to avoid lymph node removal and...
Read MoreHow effective is routine treatment with trastuzumab in early breast cancer?
In a nutshell This study investigated the role of trastuzumab (Herceptin) as part of standard care in patients with human epidermal growth factor receptor-2 positive (HER2+) early breast cancer (BC). The study conclude that trastuzumab was effective in general practice, including patients not often included in clinical trials (such as the...
Read MoreThe use of MR imaging to predict invasive breast cancer prognosis
In a nutshell This study investigated the use of magnetic resonance (MR) imaging as a prognostic tool in primary breast cancer (BC) patients. The study concluded that MR imaging can identify features which can be used to help predict the risk of distant metastasis (cancer spread to other areas) in patients. Some background Between 20-30%...
Read More
